Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
Rebecca C Abbott, Ryan S. Cross, Misty R. Jenkins
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 2, pp. 515-515
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, et al.
Molecular Therapy (2020) Vol. 28, Iss. 11, pp. 2320-2339
Open Access | Times Cited: 297
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma
Luke Maggs, Giulia Cattaneo, Ali Emre Dal, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 115
CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application
Yu-Huan Yang, Jiawei Liu, Lü Chen, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 6, pp. 2609-2626
Open Access | Times Cited: 84
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alaa Alnefaie, Sarah Albogami, Yousif A. Asiri, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 74
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Man Wang, Fei Yu, Yuan Zhang
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 11
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Salma Khan, Yeonjoo Choi, Mysore S. Veena, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 6
Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Sundee Dees, Rajkumar Ganesan, Sanjaya Singh, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 12, pp. 2409-2421
Open Access | Times Cited: 93
The state of the art of bispecific antibodies for treating human malignancies
Shuhang Wang, Kun Chen, Qi Lei, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 9
Open Access | Times Cited: 65
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Chiara Corti, Konstantinos Venetis, Elham Sajjadi, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 593-605
Open Access | Times Cited: 54
Injectable hydrogels for personalized cancer immunotherapies
Neda Mohaghegh, Amir Ahari, Fatemeh Zehtabi, et al.
Acta Biomaterialia (2023) Vol. 172, pp. 67-91
Open Access | Times Cited: 32
CAR-T cell therapy for hematological malignancies: History, status and promise
Chao Wang, Jianpeng Wang, Shusheng Che, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21776-e21776
Open Access | Times Cited: 26
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
Hassan Dana, Ghanbar Mahmoodi Chalbatani, Seyed Amir Jalali, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 5, pp. 1129-1147
Open Access | Times Cited: 70
Antigen Specificity Enhances Disease Control by Tregs in Vitiligo
Zhussipbek Mukhatayev, Emilia R. Dellacecca, Cormac Cosgrove, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 56
To go or not to go? Biological logic gating engineered T cells
Rebecca C Abbott, Hannah E Hughes‐Parry, Misty R. Jenkins
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e004185-e004185
Open Access | Times Cited: 34
Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Chaojie Zhu, Qing Wu, Tao Sheng, et al.
Bioactive Materials (2023) Vol. 33, pp. 377-395
Open Access | Times Cited: 22
Applications of the phage display technology in molecular biology, biotechnology and medicine
Karolina Pierzynowska, Joanna Morcinek-Orłowska, Lidia Gaffke, et al.
Critical Reviews in Microbiology (2023) Vol. 50, Iss. 4, pp. 450-490
Closed Access | Times Cited: 18
Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches
Yoshiaki Yura, Masakazu Hamada
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11179-11179
Open Access | Times Cited: 17
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, et al.
Haematologica (2021) Vol. 106, Iss. 8, pp. 2054-2065
Open Access | Times Cited: 34
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma
Rebecca C Abbott, Daniel J. Verdon, Fiona M. Gracey, et al.
Clinical & Translational Immunology (2021) Vol. 10, Iss. 5
Open Access | Times Cited: 34
HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma
Stacie Shiqi Wang, Alexander J. Davenport, Melinda Iliopoulos, et al.
Neuro-Oncology Advances (2023) Vol. 5, Iss. 1
Open Access | Times Cited: 16
Recent advancement in breast cancer treatment using CAR T cell therapy:- A review
Anuvab Dey, Subhrojyoti Ghosh, Shreya Jha, et al.
Advances in Cancer Biology - Metastasis (2023) Vol. 7, pp. 100090-100090
Open Access | Times Cited: 14
Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
Anna Szulc, Marta Woźniak
Cancers (2024) Vol. 16, Iss. 8, pp. 1483-1483
Open Access | Times Cited: 6
Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Eline van Diest, Patricia Hernández López, Angelo D. Meringa, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 11, pp. e003850-e003850
Open Access | Times Cited: 31
Better by design: What to expect from novel CAR-engineered cell therapies?
Vera Luginbuehl, Eytan Abraham, Karin Kovar, et al.
Biotechnology Advances (2022) Vol. 58, pp. 107917-107917
Closed Access | Times Cited: 22
CAR-T cell therapy in advanced thyroid cancer: from basic to clinical
Zhenhua Sun, Chaohui Wang, Yuyang Zhao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top